ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Transplantation · Bone Marrow Transplant · 2026-08-21

In a randomised pilot trial of 79 patients with AML or MDS having 8/8 HLA-matched donor transplants, ATG plus post-transplant cyclophosphamide gave similar 100-day survival to ATG alone (94.9% vs 95.0%, p>0.9); median neutrophil engraftment was slower (22 vs 19 days).

RCTn = 79
Walker et al. A randomized pilot trial comparing anti-thymocyte globulin with anti-thymocyte globulin plus post transplant cyclophosphamide for prophylaxis against acute and chronic graft versus host disease in matched donor hematopoietic cell transplants - a study from the Cell Therapy Transplant Canada/ Australasian Leukemia Lymphoma Group Consortium
Oncology · Lancet Oncol · 2026-07-01

In 174 women with stage III HER2-negative HRD breast cancer, intensified alkylating chemotherapy with stem cell rescue gave no 4-year overall survival advantage over chemotherapy then olaparib (77.0% vs 76.4%; HR 1.11), with more serious adverse events (47% vs 26%).

RCTn = 174
Seefat et al. Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial
Haematology · Br J Haematol · 2026-06-16

In 104 patients with relapsed-refractory multiple myeloma, adding cyclophosphamide to pomalidomide-dexamethasone did not significantly improve progression-free survival (median 6.9 vs 4.6 months); the phase 2 trial closed early and was underpowered. Response rate was higher.

RCTn = 104
Hall et al. Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial
Oncology · ESMO Open · 2025-11-27

In 10-year registry follow-up of 699 PlanB trial patients with HR-positive, HER2-negative early breast cancer, invasive disease-free survival was similar with six cycles of TC and with EC-T (90.8% vs 92.1%, P = 0.546); overall survival was 96.8% vs 96.3%.

RCTn = 699
Nitz et al. Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.